Abstract

Ovarian cancer remains a formidable challenge in oncology, with an estimated 313,000 new cases diagnosed globally each year.1 It is often dubbed the “silent killer” due to its asymptomatic nature in the early stages, leading to late diagnoses and poor prognoses.2 Recent advancements in diagnostic and therapeutic strategies are pivotal in altering this narrative, aiming to improve survival rates and quality of life for patients.

Keywords

Ovarian cancer, diagnoses, biomarkers